Business Context and Reporting Period
This Form 8-K is a current report filed by Nephros, Inc. on August 17, 2009. The filing addresses corporate governance changes rather than financial performance or operational results.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report is limited to the appointment of a director and contains no financial data.
Material Changes
The material change reported is the appointment of Ernest Elgin, III to the Board of Directors on August 17, 2009. Mr. Elgin, who has served as the company's President and Chief Executive Officer since September 2008, will hold the director position until the 2010 Annual Meeting of Stockholders or until his successor is elected. He was not appointed to any specific Board committees.
Guidance, Outlook, and Risks
The filing contains no guidance, outlook, management commentary on financial performance, risks, contingencies, or unusual items. It strictly details the director appointment and Mr. Elgin's professional background, which includes 20 years of experience in healthcare and business development roles at organizations such as Novaflux, EHC Group, Becton Dickinson, and Olympus America.
Investor Verification Checklist
- Verify the effective date of Ernest Elgin, III's appointment to the Board of Directors.
- Confirm that no additional compensatory arrangements were made for this appointment beyond existing employment agreements.
- Note that this filing does not contain updated financial statements or operational metrics.